Evidence map›Paper›PMID 34416147›Full record

ArticleCell2021

Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress.

Lauren E Williamson, Kristen M Reeder, Kevin Bailey, Minh H Tran, Vicky Roy, Mallorie E Fouch, Nurgun Kose, Andrew Trivette, Rachel S Nargi, Emma S Winkler and 18 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Demonstration ofJournal of virology · 2026
    Article
  9. Development ofEmerging microbes & infections · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 7 institutions in 2 countries.

Lauren E WilliamsonDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232, USA; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Kristen M ReederThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Kevin BaileyInstitute for Antiviral Research, Utah State University, Logan, UT 84335, USA.
Minh H TranChemical and Physical Biology Program, Vanderbilt University, Nashville, TN, USA; Center of Structural Biology, Vanderbilt University, Nashville, TN, USA; Department of Biochemistry and Mass Spectrometry Research Center, Vanderbilt University, Nashville, TN, USA.
Vicky RoyRagon Institute of MGH, MIT, and Harvard University, Cambridge, MA 02139, USA.
Mallorie E FouchIntegral Molecular, Philadelphia, PA 19104, USA.
Nurgun KoseThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Andrew TrivetteThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Rachel S NargiThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Emma S WinklerDepartment of Medicine, Washington University, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.
Arthur S KimDepartment of Medicine, Washington University, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA.
Christopher GainzaThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Jessica RodriguezThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Erica ArmstrongThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Rachel E SuttonThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Joseph ReidyThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Robert H CarnahanThe Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
W Hayes McDonaldDepartment of Biochemistry and Mass Spectrometry Research Center, Vanderbilt University, Nashville, TN, USA.
Clara T SchoederCenter of Structural Biology, Vanderbilt University, Nashville, TN, USA; Department of Chemistry, Vanderbilt University, Nashville, TN, USA.
William B KlimstraThe Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA 165261, USA; Department of Immunology, University of Pittsburgh, Pittsburgh, PA 165261, USA.
Edgar DavidsonIntegral Molecular, Philadelphia, PA 19104, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, PA 19104, USA.
Galit AlterRagon Institute of MGH, MIT, and Harvard University, Cambridge, MA 02139, USA.
Jens MeilerCenter of Structural Biology, Vanderbilt University, Nashville, TN, USA; Department of Chemistry, Vanderbilt University, Nashville, TN, USA; Institute for Drug Discovery, Leipzig University Medical School, Leipzig, Germany.
Kevin L ScheyDepartment of Biochemistry and Mass Spectrometry Research Center, Vanderbilt University, Nashville, TN, USA.
Justin G JulanderInstitute for Antiviral Research, Utah State University, Logan, UT 84335, USA.
Michael S DiamondDepartment of Medicine, Washington University, St. Louis, MO 63110, USA; Department of Pathology and Immunology, Washington University, St. Louis, MO 63110, USA; Department of Molecular Microbiology, Washington University, St. Louis, MO 63110, USA.
James E CroweDepartment of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; The Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: james.crowe@vumc.org.
Vanderbilt University Medical Center · USVanderbilt University · USIntegral Molecular (United States) · USWashington University in St. Louis · USRagon Institute of MGH, MIT and Harvard · USUtah State University · USUniversity of Pittsburgh · US

Funding

The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI DIAMOND, MICHAEL S · 2019 to 2023
$40.0M
TRAINING PROGRAM IN IMMUNOLOGY AND IMMUNOGENETICST32AI007163 · NIAID · WASHINGTON UNIVERSITY · PI Kenneth M Murphy, Kodi S Ravichandran · 1985 to 2026
$14.8M
B-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins 75N93019C00073 · NIAID · INTEGRAL MOLECULAR · PI DORANZ, BENJAMIN · 2019 to 2023
$7.5M
Immunobiology of Blood and Vascular Systems Training ProgramT32HL069765 · NHLBI · VANDERBILT UNIVERSITY · PI HAWIGER, JACK J · 2002 to 2016
$6.5M
Molecular Mechanisms of Eastern Equine Encephalitis Virus PathogenesisR01AI095436 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KLIMSTRA, WILLIAM B · 2012 to 2022
$4.5M
High-Performance Computer Cluster for Biomedical ResearchS10OD023680 · OD · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2017 to 2017
$587k
Hybrid Methods for Prediction and Design of Novel Human Influenza AntibodiesR56AI110750 · NIAID · VANDERBILT UNIVERSITY · PI CROWE, JAMES E, MEILER, JENS · 2014 to 2014
$433k
Regulation of Antiviral Responses in Plasmacytoid Dendritic Cells to Chikungunya Virus by the Gut MicrobiotaF30AI152327 · NIAID · WASHINGTON UNIVERSITY · PI WINKLER, EMMA SUENING · 2021 to 2022
$84k
Neutralization of Eastern equine encephalitis virus by human monoclonal antibodiesF31AI145189 · NIAID · VANDERBILT UNIVERSITY · PI WILLIAMSON, LAUREN · 2019 to 2020
$49k
NCATS NIH HHS UL1 TR000445NHLBI NIH HHS T32 HL069765NIAID NIH HHS 75N93019C00073NIAID NIH HHS F30 AI152327NIAID NIH HHS F31 AI145189NIAID NIH HHS R01 AI095436NIAID NIH HHS R56 AI110750NIAID NIH HHS T32 AI007163NIAID NIH HHS U19 AI142790NIH HHS S10 OD023680
6 · The paper itself

Abstract

Alphaviruses cause severe arthritogenic or encephalitic disease. The E1 structural glycoprotein is highly conserved in these viruses and mediates viral fusion with host cells. However, the role of antibody responses to the E1 protein in immunity is poorly understood. We isolated E1-specific human monoclonal antibodies (mAbs) with diverse patterns of recognition for alphaviruses (ranging from Eastern equine encephalitis virus [EEEV]-specific to alphavirus cross-reactive) from survivors of natural EEEV infection. Antibody binding patterns and epitope mapping experiments identified differences in E1 reactivity based on exposure of epitopes on the glycoprotein through pH-dependent mechanisms or presentation on the cell surface prior to virus egress. Therapeutic efficacy in vivo of these mAbs corresponded with potency of virus egress inhibition in vitro and did not require Fc-mediated effector functions for treatment against subcutaneous EEEV challenge. These studies reveal the molecular basis for broad and protective antibody responses to alphavirus E1 proteins.

Indexed as

AlphavirusAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralCell LineChikungunya virusCross ReactionsEncephalitis Virus, Eastern EquineEncephalomyelitis, EquineEpitope MappingFemaleHorsesHumansHydrogen-Ion ConcentrationAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntigens, ViralReceptors, FcRNA, ViralViral Proteinsalphaviruscross-reactive antibodieshuman monoclonal antibodiesnon-neutralizing antibodiespost-exposure prophylaxis

Identifiers

PMID34416147
PMCPMC8418820
OpenAlexW3194867376

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.